Introduction
============

The clinical, human and economic burden associated with sepsis is huge \[[@B1]\]. Initiatives such as the Surviving Sepsis Campaign \[[@B2]\], launched in 2002 as a collaborative initiative of the European Society of Intensive Care Medicine, the International Sepsis Forum, and the Society of Critical Care Medicine, aim to effectively reduce risk of death from severe sepsis and septic shock. Nonetheless, although substantial benefits raised from the implementation of this campaign have been obtained, much work remains if we are to realise the full potential promised by this strategy. Recently, new treatment approaches based on interventions for coagulation or inflammation have failed to improve survival in sepsis \[[@B1]\]. In addition, more effort needs to be made in the prevention of sepsis.

Main text
=========

A deeper understanding of the processes leading to sepsis is necessary before we can design an effective suite of interventions \[[@B1]\]. Dysregulation of the immune response to infection is acknowledged to contribute to the pathogenesis of the disease \[[@B1]\]. Critical illness itself, surgery and concomitant comorbidities such as diabetes, chronic renal failure or chronic obstructive pulmonary disease affect host responses to infection \[[@B3],[@B4]\], which could in turn facilitate the development of sepsis or impair outcome once sepsis is established.

Despite these precedents, the potential role of immunological monitoring in this disease has not been appropriately considered to the present moment. For years, two phases have been described in sepsis: an initial systemic inflammatory response syndrome followed by the negative feedback of a secondary compensatory anti-inflammatory response syndrome \[[@B5],[@B6]\]. In contrast to this long-held view, Marchant and colleagues and our group have observed that production of the immunosuppressive cytokine IL-10 occurs from the very first hours following the diagnosis of severe sepsis or septic shock, and that it is directly associated with the secretion of proinflammatory cytokines \[[@B7]-[@B9]\]. In addition, hypogammaglobulinemia is often present in patients with septic shock \[[@B10]\]. Levels of IgG, IgM and IgA at diagnosis have been reported to correlate directly with survival \[[@B11],[@B12]\]. In turn, nonsurvivors have lower levels of C4 (a protein of the complement system) than survivors \[[@B11]\]. Natural killer cell counts and function also seem to have an important role in this disease \[[@B11]\]. Severe depletion of immune effector cells is a universal finding in all age groups during sepsis \[[@B6]\]. Quantification of lymphocyte subsets and evaluation of their function could thus have diagnostic and prognostic value in sepsis. At the genomic level, repression of networks corresponding to major histocompatibility complex antigen presentation is observed in paediatric patients with septic shock \[[@B13]\].

As a consequence, cumulative evidence supports the notion that the immunological situation of the patient is linked to the final outcome in sepsis. Immunological monitoring could thus contribute to the prevention or the treatment of sepsis in a personalised and timely manner.

Interestingly, there is no currently available information on the potential role of proper immunological monitoring for the prevention of sepsis. Immunological monitoring could help to identify patients with immunological deficiencies (secondary to their disease process, treatment, and so forth) at higher risk for developing community acquired or nosocomial sepsis. Periodic monitoring of patients hospitalised in key services (that is, oncology, transplantation units, critical care units) could help to identify specific humoral or cellular immunity defects that could be addressed by implementation of prophylactic measures, such as administration of intravenous immunoglobulin (IVIG) or proper cover with broad-spectrum antibiotics.

Prompt implementation of an accurate treatment is key to the final outcome in patients with sepsis \[[@B1]\]. Immunological monitoring could help to improve outcome in sepsis, by providing early detection of individuals at higher risk for developing complicated outcomes as well as relevant information for guiding treatment. For example, the treatment effect of IVIG on mortality for patients with septic shock is currently controversial. Measuring endogenous levels of immunoglobulins could improve the render of IVIG in sepsis, helping the clinician to better select those patients to be treated (those exhibiting marked hypogammaglobulinemia). Once more, there is a dramatic absence of information on the potential role of prior endogenous immunoglobulin quantification in the clinical assays evaluating IVIG for the treatment of this disease. Immunological monitoring could help also to guide therapies with immunomodulatory drugs with an anti-inflammatory effect or, alternatively, with an immunostimulatory effect \[[@B14]\].

Although not currently practiced, monitoring of the patient\'s immunological situation is feasible (at least from a quantitative point of view) in most hospitals. Quantification of immunoglobulins, complement proteins and T cells (CD4, CD8) in peripheral blood is an easily available routine test. Other tests of potential interest for immunological monitoring in sepsis include the quantification of HLA-DR in the surface of blood monocytes \[[@B15]\] or the evaluation of percentages of circulating CD4^+^CD25^+^T-regulatory cells in blood. Lastly, the use of genomic signatures (gene expression, miRNA, DNA methylation profiles) offers new opportunities to assess the immunological status of the patient. Combined evaluation of several immunological variables could provide added value over single ones.

Conclusion
==========

Although diffuse and limited, current available information supports the development of large comprehensive studies aimed to urgently evaluate immunological monitoring as a tool to prevent or treat sepsis, and thereby to diminish the morbidity and mortality associated with this severe condition.
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